NCT06561074View on ClinicalTrials.gov

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2031

Conditions
T-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
Interventions
DRUG

Decitabine

Given by vein

DRUG

Venetoclax

Given by mouth

DRUG

Calaspargase pegol-mknl

Given by vein

Trial Locations (1)

77090

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT06561074 - A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) | Biotech Hunter | Biotech Hunter